USD 3.5 billion
Report ID:
SQMIG35A2784 |
Region:
Global |
Published Date: July, 2024
Pages:
219
|Tables:
62
|Figures:
69
Vasomotor Symptoms Market was valued at USD 3.5 billion in 2022 and is expected to rise from USD 3.74 billion in 2023 to reach a value of USD 6.38 billion by 2031, at a CAGR of 6.90% during the forecast period (2024–2031).
Vasomotor symptoms stand out as the most reported symptoms of menstruation, often manifesting as hot flashes, night sweats, and anemia. These symptoms include bleeding to the neck, face and forehead suddenly, with profuse perspiration. Notably, the frequency and severity of heart palpitations symptoms vary widely among postmenopausal women, with the first two years of menopause being particularly difficult.
The severity of symptoms during this period can be debilitating. Additionally, for some women these symptoms can be permanent, highlighting the varied and individual nature of the menstrual experience Multidimensional neurological symptoms highlight the need for a through which the unique challenges faced by women in this phase of social change are highlighted.
Global Market Size
USD 3.5 billion
Largest Segment
Non-Hormonal
Fastest Growth
Non-Hormonal
Growth Rate
6.90% CAGR
To get more reports on the above market click here to Buy The Report
The vasomotor symptoms market is segmented into therapy type, distribution channel, and region. Based on therapy type, the market is segmented into Hormonal (Estrogen, Progesterone, Combination, Others), Non-Hormonal (Anti-Depressants, Others). Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online stores and others. Based on region, the market is segmented into North America, Asia Pacific, Europe, Middle East & Africa, and Latin America.
Analysis by Therapy Type
In 2023, the hormonal segment emerged as the predominant contributor to the vasomotor symptoms market revenue, commanding a substantial share of approximately 65-67%. This dominance is primarily attributed to the prevalence of hormonal therapy as a common and effective treatment option for Vasomotor Symptoms (VMS), particularly among women undergoing menopause-related symptoms.
The non-hormonal segment plays a crucial role in the vasomotor symptoms market, providing alternative treatment options for individuals seeking relief from symptoms associated with menopause and hormonal fluctuations. Unlike hormonal therapies, non-hormonal approaches offer solutions that do not involve the use of estrogen or progesterone. This segment includes diverse treatments such as selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), gabapentinoids, and lifestyle modifications.
Analysis by Distribution Channel
The hospital pharmacy segment emerges as a dominant force in the market by 2023. This number can be attributed to the growing trend of metal implants, which plays an important role in the availability of multiple pharmacies. Be sure as a calm and regulated environment ensures that patients receive appropriate medications based on their health care needs.
With the increasing popularity of online pharmacies, the online store segment is poised to exhibit rapid growth in the market. These channels have grown tremendously, facilitating not only remote shopping but also reducing its price is also attractive. Notably, initiatives like the one implemented by Tata 1 MG are an example of the trend, where customers can get up to 20% discount on allopathic medicines through online shopping If besides, users stand to gain an additional 5% discount by submitting a doctor’s note. Such models, which combine availability, discounted prices and ease of access to online prescription drugs, are expected to lead to the expansion of online stores in the market.
To get detailed analysis on other segments, Request For Free Sample Report
The North America vasomotor symptoms market is valued at US$ 1.6 billion by 2023 and is poised to exhibit a noteworthy growth rate at a compound annual growth rate (CAGR) during the analyzed period. This strong growth is primarily related to syndromes associated with vasomotor issues Besides being due to the readily available knowledge of the availability of relaxing drugs, common symptoms of inflammation widespread around the time of menopause gain market significant impact on development.
Asia Pacific is poised to record the fastest annual growth rate (CAGR) between 2024 and 2031. This growth can be attributed to several factors, including increased education among women and solutions including a designed awareness campaign that illuminates the prevalence of symptoms. Furthermore, there has been a shift in public opinion, menopause is not dismissed as a disease but accepted as an inevitable genetic part of aging.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Drivers
Increasing Research and Development and Clinical Trials
Restraints
Increased Cost of Treatment
Request Free Customization of this report to help us to meet your business objectives.
The competitive environment of the Vasomotor Symptoms market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. Leading brands invest in research and development to introduce new flavors, packaging formats, and health-focused variations to cater to changing consumer preferences. They often set the trends in the industry.
Top Player’s Company Profiles
Recent Developments
In December 2023, Astellas Pharma Inc. announced that the European Commission approved VEOZATM (fezolinetant) 45 mg once daily for treating moderate to severe vasomotor symptoms (VMS) associated with menopause.
In July 2023, Mithra Pharmaceuticals and Searchlight Pharma entered into a licensing agreement for Donesta, an investigational drug for treating menopausal symptoms. Data from two multicenter, randomized Phase III trials (C301 – NCT04209543 and C302 – NCT04090957) evaluating Donesta demonstrated a reduction in vasomotor symptoms from baseline and in comparison, to placebo.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyzes the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. The market has grown, driven in part by over-the-counter (OTC) products. OTC options are increasingly accepted by patients because of their perceived low side effects. This shift in consumer behavior towards self-care and easy access to OTC products is contributing to the overall expansion of the market. Moreover, major market players are adopting expansion strategies such as mergers and acquisitions, leading to higher market growth. A typical example is the April 2022 acquisition of women’s health specialist Bonafide.
Report Metric | Details |
---|---|
Market size value in 2022 | USD 3.5 billion |
Market size value in 2031 | USD 6.38 billion |
Growth Rate | 6.90% |
Base year | 2023 |
Forecast period | 2024–2031 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the Vasomotor Symptoms Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Vasomotor Symptoms Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Vasomotor Symptoms Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Vasomotor Symptoms Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONWant to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35A2784